During this educational webinar, oncology experts and patient advocates will discuss the therapeutic landscape of non-classical or acquired EGFR mutations within NSCLC as well as current clinical trials aimed at advancing therapeutic options in this space.
Presented by:
Ivy Elkins (Moderator)
Patient Advocate
Co-founder, EGFR Resisters
Jill Feldman (Moderator)
Patient Advocate
Co-founder, EGFR Resisters
Balazs Halmos, MD
Associate Director of Clinical Science and Professor of Oncology, Montefiore Einstein Comprehensive Cancer Center
Julia Rotow, MD
Clinical Director of the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute